Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients
Authors
Keywords
Epidermal growth factor receptor, Anaplastic lymphoma kinase, Mutation, Non-small cell lung cancer, Positron emission tomography, Standard uptake value
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 45, Issue 5, Pages 735-750
Publisher
Springer Nature
Online
2017-11-21
DOI
10.1007/s00259-017-3885-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET
- (2017) I. Bahce et al. LUNG CANCER
- The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition
- (2017) Justin Goodwin et al. Nature Communications
- Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers
- (2017) Rifeng Jiang et al. PLoS One
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) S. Novello et al. ANNALS OF ONCOLOGY
- Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer
- (2016) Arthur Cho et al. BMC CANCER
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Contribution of18Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma
- (2016) Zehra Dilek Kanmaz et al. Cancer Biomarkers
- The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers
- (2016) Ivayla Apostolova et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non–Small Cell Lung Cancer
- (2016) Stephen S.F. Yip et al. JOURNAL OF NUCLEAR MEDICINE
- ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm
- (2016) Antonio Marchetti et al. Journal of Thoracic Oncology
- Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) V. De Rosa et al. CLINICAL CANCER RESEARCH
- FDG Uptake in Non–Small Cell Lung Cancer Is Not an Independent Predictor of EGFR or KRAS Mutation Status
- (2015) Seok Mo Lee et al. CLINICAL NUCLEAR MEDICINE
- Role of Imaging Biomarkers in Predicting Anaplastic Lymphoma Kinase–Positive Lung Adenocarcinoma
- (2015) Chae Jin Jeong et al. CLINICAL NUCLEAR MEDICINE
- Metabolic Phenotype of Stage IV Lung Adenocarcinoma
- (2015) Elaine Yuen Phin Lee et al. CLINICAL NUCLEAR MEDICINE
- Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives
- (2015) Joan Minguet et al. INTERNATIONAL JOURNAL OF CANCER
- Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma
- (2015) Hideki Makinoshima et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey
- (2015) Yasushi Yatabe et al. Journal of Thoracic Oncology
- Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma
- (2014) Kai-Hsiung Ko et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer
- (2014) Carlos Caicedo et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global Metabolic Pathways in EGFR-mutated Lung Adenocarcinoma
- (2014) Hideki Makinoshima et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
- (2014) Natasha B. Leighl et al. JOURNAL OF CLINICAL ONCOLOGY
- Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing
- (2014) Carolyn J. Shiau et al. Journal of Thoracic Oncology
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histological subtypes of lung cancer in Chinese women from 2000 to 2012
- (2014) Xiao Nong Zou et al. Thoracic Cancer
- Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
- (2013) J. Ying et al. ANNALS OF ONCOLOGY
- Combined Targeting of PDK1 and EGFR Triggers Regression of Glioblastoma by Reversing the Warburg Effect
- (2013) K. K. Velpula et al. CANCER RESEARCH
- EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer
- (2013) Ivan Babic et al. Cell Metabolism
- Novel therapeutic targets in non-small cell lung cancer
- (2013) Muhammad Alamgeer et al. CURRENT OPINION IN PHARMACOLOGY
- Evaluation of 2-Year Experience With EGFR Mutation Analysis of Small Diagnostic Samples
- (2013) Katarina Hlinkova et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma
- (2013) Hyun Woo Chung et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
- (2013) Neal I. Lindeman et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
- (2012) I. Bahce et al. CLINICAL CANCER RESEARCH
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis
- (2012) Chongrui Xu et al. Journal of Hematology & Oncology
- National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China
- (2012) Cong Xue et al. LUNG CANCER
- Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT
- (2012) Hongyoon Choi et al. LUNG CANCER
- PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer
- (2011) A A Memon et al. BRITISH JOURNAL OF CANCER
- Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors
- (2011) Alexandra F. Leary et al. EUROPEAN JOURNAL OF CANCER
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations
- (2011) Y.-W. Won et al. JOURNAL OF CLINICAL PATHOLOGY
- Molecular Imaging with 11C-PD153035 PET/CT Predicts Survival in Non-Small Cell Lung Cancer Treated with EGFR-TKI: A Pilot Study
- (2011) X. Meng et al. JOURNAL OF NUCLEAR MEDICINE
- The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group
- (2011) Erik Thunnissen et al. LUNG CANCER
- Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
- (2011) R. H. Mak et al. ONCOLOGIST
- 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis
- (2009) Im Il Na et al. LUNG CANCER
- Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma
- (2009) Chun-Ta Huang et al. MEDICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
- (2008) Amit Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started